Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.65%
#2 Victoria VR Victoria VR +11.02%
#3 Palladium Network Palladium Network +8.47%
#4 Cryptopia Cryptopia +4.36%
#5 COTI COTI +3.80%
#6 GRVT Token GRVT Token +2.92%
#7 Lisk Lisk +2.64%
#8 NEAR Intents Bridged ZEC NEAR Intents Bridged ZEC +2.61%
#9 Kinetiq Kinetiq +2.57%
#10 Lighter Lighter +2.56%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Synovics Pharmaceuticals, Inc. Synovics Pharmaceuticals, Inc.

Synovics Pharmaceuticals, Inc.

SYVC
Classement en actions #42246
Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the... Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company’s OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States. The company was formerly known as Bionutrics Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006. Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Fort Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.
Prix de l'action
$0.0001
Dernière synchronisation: 2026-08-11
Capitalisation boursière
$2.98K
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Synovics Pharmaceuticals, Inc. (SYVC)

Catégorie

Healthcare
Revenus pour Synovics Pharmaceuticals, Inc. (SYVC)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Synovics Pharmaceuticals, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Synovics Pharmaceuticals, Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR